Results 71 to 80 of about 399,478 (308)
Molecular Oncology, EarlyView.In the present work, we have identified a transcriptional signature based on the differential expression of six genes (BCL2&MAST4, HSH2D&LAT2, METRN&PITPNM2) that would facilitate the early detection of T‐cell acute lymphoblastic leukemia (T‐ALL) patients prone to a poor treatment response and could be implemented at diagnosis, along with other risk ...
Antonio Lahera +11 more
wiley +1 more source
, 2009 Pharmacogenetics has its roots in the 1950s with pioneering studies of monogenic variations in drug metabolism and pharmacokinetics. With the availability of high-throughput genomics technologies and the completion of the Human Genome Project in 2003, we
core +1 more source
Personalized Medicine: A Personal View
Current Oncology, 2010 After the discovery of the breast cancer–associated genes BRCA1 in 1994 and BRCA2 in 1995, genetic testing was introduced into clinical practice in North America and Europe[...]
openaire +2 more sources
Molecular Oncology, EarlyView.CIN85 is highly expressed in osteosarcoma, particularly in metastatic lesions. Its overexpression increases cell migration and Matrigel invasion, while silencing CIN85 suppresses these behaviors. Transcriptome analysis shows that CIN85 regulates MMP2, COL3A1, and Akt/mTOR signaling. Targeting these pathways reverses CIN85‐induced motility, highlighting
Iryna Horak +10 more
wiley +1 more source
Neurotheranostics as personalized medicines
Advanced Drug Delivery Reviews, 2019 The discipline of neurotheranostics was forged to improve diagnostic and therapeutic clinical outcomes for neurological disorders. Research was facilitated, in largest measure, by the creation of pharmacologically effective multimodal pharmaceutical formulations.
Bhavesh D, Kevadiya +9 more
openaire +2 more sources
Molecular Oncology, EarlyView.Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena +15 more
wiley +1 more source
An eMERGE Clinical Center at Partners Personalized Medicine
, 2016 The integration of electronic medical records (EMRs) and genomic research has become a major component of efforts to advance personalized and precision medicine.
MacArthur, Daniel +15 more
core +1 more source
Molecular Oncology, EarlyView.Circulating tumor cells (CTCs) and plasma cell‐free DNA (cfDNA) were analyzed to detect ESR1 mutations and methylation in patients with advanced breast cancer. CTC‐derived DNA showed higher sensitivity for mutation detection and revealed complementary genetic and epigenetic alterations, highlighting the added value of CTC analysis for understanding ...
Dimitra Stergiopoulou +12 more
wiley +1 more source
Is the TOAST Classification Suitable for Use in Personalized Medicine in Ischemic Stroke?
, 2022 Pathophysiologic classification of ischemic stroke is essential to a personalized approach to stroke treatment. The Trial of Org 101072 in Acute Stroke Treatment (TOAST) classification is the most frequently used tool to classify index ischemic strokes ...
Simonsen, Sofie A. +11 more
core +1 more source
Frontiers in Microbiology, 2020 Altered composition of the gut microbiota has been observed in many neurodegenerative diseases. LanCL1 has been proven to protect neurons and reduce oxidative stress.
Fangxing Zhang +30 more
doaj +1 more source